Amgen, Oklahoma Health Care Authority and University of Oklahoma's Pharmacy Management Consultants partner to improve medicaid outcomes

AmgenThe Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC) and Amgen (NASDAQ:AMGN) announced a new collaborative agreement to help improve clinical outcomes, experience and satisfaction for Oklahoma's 796,000 SoonerCare (Oklahoma Medicaid) members. Results from the projects also could lay the groundwork for innovative ways to look at patient outcomes and measures for medication reimbursement.

"I look forward to this collaboration providing valuable insights that will help improve patient outcomes and save money. It fully aligns with our goal to foster collaboration among public and private individuals and entities to build a responsive health care system for Oklahoma," said Nancy Nesser, J.D., Pharm.D., OHCA Pharmacy director.

The parties intend for initial research projects to use de-identified claims data to gain insights about medication adherence, missed diagnoses, heightened disease risk and other clinical indicators in Oklahoma's SoonerCare population. Disease states of special interest to each participant include autoimmune diseases, bone health/osteoporosis, migraine and oncology care. The expectation is that findings from the research will help support the development of preventive measures - for instance, identifying post fracture patients and working to educate them on the importance of disease management. In many cases, the cost of preventive therapy is a fraction of the cost of hospitalization, and valuable to the patient's health and well-being. Collectively, this information can help optimize overall patient outcomes and minimize unnecessary healthcare spending across the country.

"This is an exciting collaboration for PMC because it closely fits with the data analysis we already undertake for OHCA on pharmaceutical utilization and outcomes," said Terry Cothran, R.Ph., PMC director. Projects will be jointly managed by PMC and Amgen, with PMC performing research services funded by Amgen.

"Leveraging our collaborative research experience and population health unit, Amgen is excited to engage in our first partnership with a state Medicaid agency to evaluate and gain insights on Medicaid health plan data. Through this unique partnership, we look forward to working with OHCA and PMC to apply that information in identifying opportunities, including value-based programs, to improve costs, quality of care and the patient experience in Oklahoma," said Peter Juhn M.D., M.P.H., vice president of Global Value-Based Partnerships at Amgen.

Globally, Amgen is engaged in over 75 distinct, value-based projects, spanning disease state collaborations, risk sharing, cost-cap programs, and outcomes-based agreements. The company has more than 25 ongoing partnerships in the United States and has several other collaborations under development.

About the Oklahoma Health Care Authority (OHCA)

OHCA administers two health programs for the state. The first is SoonerCare, Oklahoma's Medicaid program. SoonerCare works to improve the health of qualified Oklahomans by ensuring that medically necessary benefits and services are available. Qualifying Oklahomans include certain low-income children, seniors, the disabled, those being treated for breast or cervical cancer and those seeking family planning services. The second program OHCA operates is Insure Oklahoma, which assists qualifying adults and small business employees in obtaining health care coverage for themselves and their families. Currently, there are 814,806 Oklahomans enrolled in OHCA's programs. The agency contracts with a state-wide network of 46,449 providers.

About Pharmacy Management Consultants

Pharmacy Management Consultants, managed by the University of Oklahoma College of Pharmacy, provides operational, consultant and educational services to OHCA through a professional services contract with the University of Oklahoma College of Pharmacy. These services primarily support OHCA in its administration of pharmacy benefits to Oklahoma SoonerCare members and in its efforts to meet Federal OBRA requirements related to Drug Utilization Review.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...